ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1519

Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Abstract Number: 1520

Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Abstract Number: 1521

Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Abstract Number: 1522

Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Abstract Number: 1523

Genetic architecture and translational insights for SLE progression from preclinical stages
Abstract Number: 1524

Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
Abstract Number: 1525

Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Abstract Number: 1526

Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Abstract Number: 1527

Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
Abstract Number: 1528

Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
Abstract Number: 1529

Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Abstract Number: 1530

The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Abstract Number: 1531

Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Abstract Number: 1532

Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Abstract Number: 1533

Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].